New Interactive Case Study
Expert Panel Member Christopher P. Cannon, MD, addresses the impact of comorbidity and patient adherence on the efficacy of antiplatelet therapy. Data from recent studies are included throughout the activity, with emphasis on considerations for special populations. Earn 0.75 AMA PRA Category 1 Credit™ instantly!
|
Interactions Between Clopidogrel and PPIs in Audio Journal Club
Expert Panel Members David J. Schneider, MD, and Christopher B. Granger, MD, discuss the risk for adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors. Earn 0.50 AMA PRA Category 1 Credits™ instantly!
|
Clinician's Challenge: Antiplatelet Therapy Post-DES Implantation
In this Clinician's Challenge, plateletNEWS.org Expert Panel Member Marc Cohen, MD, and colleagues, Nicolai Mejevoi, MD, PhD, and Catalin Boiangiu, MD, address challenges concerning prescribing antiplatelet therapy to patients who have undergone drug-eluting stent implantation. Earn 0.75 AMA PRA Category 1 Credit™ instantly!
|
Clinical Insights® in Platelet Management
New data on the effects of concomitant use of clopidogrel with proton pump inhibitors (PPIs), aspirin use for cardiovascular disease prevention, and more. Expert Panel Member Matthew J. Price, MD, provides insights on the significance of these advances to clinical practice.
|
A Journal Club for Primary Care—Intervention & Prevention: Keeping Current with ACS
Issue 4 now available! The Acute Coronary Syndrome Journal Club summarizes key scientific advances and clinical lessons from the literature and presents commentary and insight from recognized experts in the field who treat patients with ACS.
|
Insights on EARLY ACS
Our latest literature selections explore outcomes for treating clopidogrel hypersensivity without drug interruption, aspirin noncompliance in ACS, and the EARLY ACS trial, featuring expert clinical commentary from Expert Panel Member Christopher P. Cannon, MD.
|
FDA Early Communication on Clopidogrel and Proton Pump Inhibitors
The United States Food and Drug Administration has issued an early communication regarding an ongoing safety review of clopidogrel bisulfate, particularly when taken with proton pump inhibitors (PPIs). For more information and to view the full report, click here.
|